Christopher John Lindsell

Christopher John Lindsell

Auto-generated profile, based on publicly available information

Christopher John Lindsell

Duke University

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2008 in Blood
Verified
Journal Article
Open access
PDF file
RCRobert M Cohen
Robert M Cohen
RFRobert S. Franco
Robert S. Franco
PKParamjit K. Khera
Paramjit K. Khera
ESEric P. Smith
Eric P. Smith
CLChristopher J. Lindsell
Christopher J. Lindsell
CJClinton H. Joiner
Clinton H. Joiner
Although red blood cell (RBC) life span is a known determinant of percentage hemoglobin A1c (HbA1c), its variation has been considered insufficient to affect clinical decisions in hematologically normal persons. However, an unexplained discordance between HbA1c and other measures of glycemic control can be observed that could be, in part, the result of differences in RBC life span. To explore the hypothesis that variation in RBC life span could alter measured HbA1c sufficiently to explain some of this discordance, we determined RBC life span using a biotin label in 6 people with diabetes and 6 nondiabetic controls. Mean RBC age was calculated from the RBC survival curve for all circulating RBCs and for labeled RBCs at multiple time points as they aged. In addition, HbA1c in magnetically isolated labeled RBCs and in isolated transferrin receptor-positivereticulocytes was used to determine the in vivo synthetic rate of HbA1c. The mean age of circulating RBCs ranged from 39 to 56 days in diabetic subjects and 38 to 60 days in nondiabetic controls. HbA1c synthesis was linear and correlated with mean whole blood HbA1c (R2 = 0.91). The observed variation in RBC survival was large enough to cause clinically important differences in HbA1c for a given mean blood glucose.

7 November 2009 in Neurocritical Care
Verified
Journal Article
Closed access
PDF file
JSJerzy P. Szaflarski
Jerzy P. Szaflarski
KSKiranpal S. Sangha
Kiranpal S. Sangha
CLChristopher J. Lindsell
Christopher J. Lindsell
LSLori Shutter
Lori Shutter

1 March 2008 in Stroke
Verified
Journal Article
Closed access
PDF file
DKDawn Kleindorfer
Dawn Kleindorfer
CLChristopher J. Lindsell
Christopher J. Lindsell
LBLawrence Brass
Lawrence Brass
WKWalter Koroshetz
Walter Koroshetz
JBJoseph P. Broderick
Joseph P. Broderick
Background and Purpose— Current US estimates of recombinant tissue plasminogen activator (rt-PA) use have been based either on extrapolation of regional studies or on administrative database estimates, both of which may have inherent biases. We sought to compare the utilization of rt-PA in acute ischemic stroke in the MEDPAR database to another national hospital database with drug utilization information. Methods— Cases were defined as DRG 14,15, and 524 and ICD-9 code 99.1, which indicates cerebral thrombolysis, for fiscal year 2001 to 2004. Additionally, the Premier database was queried for rt-PA utilization documented in pharmacy records in those patients admitted for stroke. Change over time and difference between databases were tested using Poisson regression. Results— When comparing databases, rt-PA use, as identified by ICD-9 code 99.1, was only documented in 0.95% of stroke cases in 2004 in MEDPAR, and 1.2% in the Premier database, which slightly increased by 0.04% to 0.09% over time. Analysis of pharmacy billing records increased the estimate to 1.82%. Exclusion of cases younger than 65years excluded 43% of cases treated with rt-PA. In 2004, 12.7% of cases receiving thrombolytic had either a TIA or a hemorrhagic stroke ICD-9 code. Conclusions— We estimate the rate of rt-PA use in the United States to be 1.8% to 2.1% of ischemic stroke patients. The rate of thrombolytic use for ischemic stroke was slightly increasing between 2001 and 2004 at a rate of 0.04% to 0.09% per year. A significant proportion of patients treated with rt-PA are likely miscoded as either TIA or hemorrhagic stroke. We conservatively estimate that 10 800 to 12 600 patients received rt-PA in 2004.

1 January 2006 in Annals of Emergency Medicine
Verified
Journal Article
Closed access
SCSean P. Collins
Sean P. Collins
CLChristopher J. Lindsell
Christopher J. Lindsell
ASAlan B. Storrow
Alan B. Storrow
WAWilliam T. Abraham
William T. Abraham

1 October 2012 in Critical Care
Verified
Journal Article
Open access
PDF file
HWHector R Wong
Hector R Wong
SSShelia Salisbury
Shelia Salisbury
QXQiang Xiao
Qiang Xiao
NCNatalie Z Cvijanovich
Natalie Z Cvijanovich
MHMark Hall
Mark Hall
CLChristopher J Lindsell
Christopher J Lindsell
Introduction: The intrinsic heterogeneity of clinical septic shock is a major challenge. For clinical trials, individual patient management, and quality improvement efforts, it is unclear which patients are least likely to survive and thus benefit from alternative treatment approaches. A robust risk stratification tool would greatly aid decision-making. The objective of our study was to derive and test a multi-biomarker-based risk model to predict outcome in pediatric septic shock. Methods: Twelve candidate serum protein stratification biomarkers were identified from previous genome-wide expression profiling. To derive the risk stratification tool, biomarkers were measured in serum samples from 220 unselected children with septic shock, obtained during the first 24 hours of admission to the intensive care unit. Classification and Regression Tree (CART) analysis was used to generate a decision tree to predict 28-day all-cause mortality based on both biomarkers and clinical variables. The derived tree was subsequently tested in an independent cohort of 135 children with septic shock. Results: The derived decision tree included five biomarkers. In the derivation cohort, sensitivity for mortality was 91% (95% CI 70 - 98), specificity was 86% (80 - 90), positive predictive value was 43% (29 - 58), and negative predictive value was 99% (95 - 100). When applied to the test cohort, sensitivity was 89% (64 - 98) and specificity was 64% (55 - 73). In an updated model including all 355 subjects in the combined derivation and test cohorts, sensitivity for mortality was 93% (79 - 98), specificity was 74% (69 - 79), positive predictive value was 32% (24 - 41), and negative predictive value was 99% (96 - 100). False positive subjects in the updated model had greater illness severity compared to the true negative subjects, as measured by persistence of organ failure, length of stay, and intensive care unit free days. Conclusions: The pediatric sepsis biomarker risk model (PERSEVERE; PEdiatRic SEpsis biomarkEr Risk modEl) reliably identifies children at risk of death and greater illness severity from pediatric septic shock. PERSEVERE has the potential to substantially enhance clinical decision making, to adjust for risk in clinical trials, and to serve as a septic shock-specific quality metric.

1 October 2006 in Stroke
Verified
Journal Article
Closed access
PDF file
EJEdward C. Jauch
Edward C. Jauch
CLChristopher Lindsell
Christopher Lindsell
JBJoseph Broderick
Joseph Broderick
SFSusan C. Fagan
Susan C. Fagan
BTBarbara C. Tilley
Barbara C. Tilley
SLSteven R. Levine
Steven R. Levine
Background and Purpose— Biochemical markers of acute neuronal injury may aid in the diagnosis and management of acute ischemic stroke. Serum samples from the National Institute for Neurological Disorders and Stroke (NINDS) recombinant tissue plasminogen activator Stroke Study were analyzed for the presence of 4 biochemical markers of neuronal, glial, and endothelial cell injury. These biochemical markers, myelin basic protein (MBP), neuron-specific enolase (NSE), S100β, and soluble thrombomodulin, were studied for an association with initial stroke severity, infarct volume, and functional outcome. Methods— In the original NINDS study, serum samples were drawn from all patients on presentation to the Emergency Department and at ≈2 and 24 hours after initiation of study therapy. In this analysis, stored serum samples were available for 359 patients; 107 patients had samples for all 3 time points. Serum marker concentrations were measured by ELISA techniques. We examined the relation between serum concentrations of each marker and the degree of baseline neurological deficit, functional outcome, and infarct size on computed tomography at 24 hours and the effect of fibrinolytic therapy. Results— Higher 24-hour peak concentrations of MBP, NSE, and S100β were associated with higher National Institutes of Health Stroke Scale baseline scores ( r =0.186, P <0.0001; r =0.117, P =0.032; and r =0.263, P <0.0001, respectively). Higher peak concentrations of MBP and S100β ( r =0.209, P <0.0001; r =0.239, P <0.0001) were associated with larger computed tomography lesion volumes. Patients with favorable outcomes had smaller changes in MBP and S100β ( P <0.05) concentrations in the first 24 hours. Soluble thrombomodulin was not associated with any severity or outcome measure. Conclusions— This study corroborates previous work demonstrating correlations of MBP, NSE, and S100β with clinical and radiographic features in acute stroke. Despite significantly better outcomes in the tissue plasminogen activator–treated group, we found no difference in the early release of the 4 biomarkers between treatment groups. Further study will define the role of biomarkers in acute stroke management and prognostication.